Cardiovascular and vascular cell therapy and tissue engineering

In the medical technology arena, the markets that draw the most attention (i.e., investment) are those that have historically had the biggest successes (i.e., revenues) due to their ability to have big impact on clinical outcomes.

Therefore, a clinical field beginning to draw much "attention" is in applications of cell therapy and tissue engineering for a range of disorders and conditions in cardiology and vascular medicine, based on these areas having driven much investment/revenue historically.

Cardiovascular and vascular applications of cell/tissue engineering encompass treatments for:

  • Coronary Heart Disease
  • Myocardial Infarction
  • Congestive Heart Failure
  • Dysfunctional Heart Valves
  • Peripheral Vascular Disorders
  • Abdominal Aortic Aneurysm

Many companies have active initiatives in the development of cardiovascular and vascular cell therapies and tissue engineering, with products at the various stages of developmental/preclinical, clinical and even a handful of approved/marketed. These include:

3DM Inc., Aastrom Bioscience Inc., Advanced Cell Technology, Inc., AdvanSource Biomaterials, Aldagen, Inc., Angioblast Systems, Inc., Angiotech Pharmaceuticals, Inc., Arteriocyte Medical Systems, Inc., Athersys, Inc., Baxter International Inc., BeFutur Biotechnologies, Bio Nova International, Bioheart Inc., California Stem Cell Inc., Capstone Therapeutics, CellSeed, Inc., Cook Group, CryoLife, Inc., Cytograft Tissue Engineering, Cytori Therapeutics Inc., ES Cell International, Garnet BioTherapeutics, Genzyme Corporation, Geron Corporation, Humacyte, Kensey Nash, Medtronic, Mesoblast Limited, MG Biotherapeutics, LLC, Miltenyi Biotec, NellOne Therapeutics, Inc., Organovo, Osiris Therapeutics Inc., Pluristem Therapeutics, Inc., ReNeuron Ltd., Stem Cell Therapy International, Inc. / Histostem, Targeted Genetics Corporation, Tepha Inc., and TriStem Corporation


See "Tissue Engineering, Cell Therapy & Transplantation Worldwide, 2009-2018." Report #S520.

Leave a Reply